Fluoguide AS
Fluoguide AS develops and commercializes advanced medical equipment and technology, primarily focused on diagnostic and therapeutic solutions in the healthcare sector.
Business. Fluoguide AS (FLUO.ST) is a healthcare company specializing in advanced medical equipment and technology. The firm operates within the Healthcare Services & Equipment industry, focusing on the development and sale of medical devices. Headquartered in Norway, the company is primarily listed on the Nasdaq Stockholm exchange. Specific details regarding operating segments and geographic revenue mix are not disclosed in the available data.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Fluoguide AS (FLUO.ST) is a healthcare company specializing in advanced medical equipment and technology. The firm operates within the Healthcare Services & Equipment industry, focusing on the development and sale of medical devices. Headquartered in Norway, the company is primarily listed on the Nasdaq Stockholm exchange. Specific details regarding operating segments and geographic revenue mix are not disclosed in the available data.
Fluoguide's capital structure is characterized by a debt-to-equity ratio of 1.81, indicating a relatively high leverage position. The company's liquidity is assessed as medium, with a current ratio of 1.31, suggesting it has sufficient short-term assets to cover its short-term liabilities, but with limited buffer. The company reported negative operating and free cash flows of -10.67 million DKK and -8.19 million DKK, respectively, indicating ongoing cash burn.
Profitability metrics are negative, with a return on equity of -127.89% and a return on assets of -36.48%, both significantly below the industry median for advanced medical equipment and technology firms. The company's operating income and net income were -8.35 million DKK and -7.52 million DKK, respectively, reflecting a challenging operating environment.
Fluoguide's revenue concentration is not disclosed in the available data, but the absence of segment or geographic breakdowns suggests a lack of diversification in its revenue streams. The company's financial snapshot does not provide segment-specific data, making it difficult to assess the contribution of different product lines or geographic regions to overall performance.
The company's growth trajectory is uncertain, with no revenue reported in the latest financial period and a net loss of 7.52 million DKK. Analysts have set a mean price target of 74.00 DKK, but the lack of revenue and negative earnings suggest a high degree of uncertainty in future performance. The absence of revenue growth in the latest period indicates a need for significant operational or strategic changes to drive future growth.
Risk factors include medium liquidity risk and a negative net cash position after subtracting total debt. The company's dilution risk is assessed as low, with no near-term pressure from share issuance or convertible debt. However, the negative operating and free cash flows suggest a potential need for external financing, which could increase dilution risk in the future.
Recent events include the publication of the latest financial results, which show no revenue and significant losses. Analysts have provided a consistent price target of 74.00 DKK, but the lack of revenue and negative earnings suggest a cautious outlook. The company has not disclosed any recent strategic initiatives or product launches that could drive future revenue growth.
- Fluoguide is operating at a significant loss with no revenue reported in the latest period.
- The company's capital structure is highly leveraged, with a debt-to-equity ratio of 1.81.
- Profitability metrics are negative, with a return on equity of -127.89%.
- Analysts have set a consistent price target of 74.00 DKK, but the company's financial performance suggests a high degree of uncertainty.
- The company's liquidity is assessed as medium, with a current ratio of 1.31.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Revenue kr 0.00; Operating income −20,5% YoY.
- ▍Revenue kr 0.00
- ▍Operating income −20,5% YoY
- ▍Net income −36,3% YoY
- ▍Free cash flow −32,5% YoY
Revenue kr 0.00; Operating income +24,8% YoY.
- ▍Revenue kr 0.00
- ▍Operating income +24,8% YoY
- ▍Net income +24,5% YoY
- ▍Free cash flow +23,0% YoY
Revenue kr 0.00; Operating income −35,3% YoY.
- ▍Revenue kr 0.00
- ▍Operating income −35,3% YoY
- ▍Net income −40,4% YoY
- ▍Free cash flow −40,4% YoY
Operating income −12,7% YoY; Net income −15,0% YoY.
- ▍Operating income −12,7% YoY
- ▍Net income −15,0% YoY
- ▍Free cash flow −15,0% YoY
Operating income -kr 28.8M.
- ▍Operating income -kr 28.8M
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -2,99 |
| Revenue | —no estimate | —no estimate | 0 DKK |
| Operating income | —no estimate | —no estimate | -51,5M DKK |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Return On Assetsnet_income / total_assets
- Fluoguide AS Market data — financials · 2026-05-27
- Fluoguide AS Market data — analyst estimates · 2026-05-27